Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders.

Wiesinger M, Stoica D, Roessner S, Lorenz C, Fischer A, Atreya R, Neufert CF, Atreya I, Scheffold A, Schuler-Thurner B, Neurath MF, Schuler G, Voskens CJ.

Front Immunol. 2017 Oct 26;8:1371. doi: 10.3389/fimmu.2017.01371. eCollection 2017.


Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis.

Voskens CJ, Fischer A, Roessner S, Lorenz C, Hirschmann S, Atreya R, Neufert C, Atreya I, Neurath MF, Schuler G.

Inflamm Bowel Dis. 2017 Aug;23(8):1348-1359. doi: 10.1097/MIB.0000000000001192.


The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.

Zundler S, Fischer A, Schillinger D, Binder MT, Atreya R, Rath T, Lopez-Pósadas R, Voskens CJ, Watson A, Atreya I, Neufert C, Neurath MF.

Inflamm Bowel Dis. 2017 Mar;23(3):379-391. doi: 10.1097/MIB.0000000000001029.


Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells.

Dietel B, Cicha I, Voskens CJ, Verhoeven E, Achenbach S, Garlichs CD.

Atherosclerosis. 2013 Sep;230(1):92-9. doi: 10.1016/j.atherosclerosis.2013.06.014. Epub 2013 Jul 10.


The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.

Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM.

PLoS One. 2013;8(1):e53745. doi: 10.1371/journal.pone.0053745. Epub 2013 Jan 14.


Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.

Voskens CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam M, Gastman B, Papadimitriou JC, Lu C, Tan M, Morales R, Cullen K, Celis E, Mann D, Strome SE.

Head Neck. 2012 Dec;34(12):1734-46. doi: 10.1002/hed.22004. Epub 2012 Jan 27.


CD137 promotes proliferation and survival of human B cells.

Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, Zhang Y, Lin W, Li G, Burch E, Tan M, Hertzano R, Chapoval AI, Tamada K, Gastman BR, Schulze DH, Strome SE.

J Immunol. 2010 Jan 15;184(2):787-95. doi: 10.4049/jimmunol.0901619. Epub 2009 Dec 11.


Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome.

Voskens CJ, Strome SE, Sewell DA.

Curr Mol Med. 2009 Aug;9(6):683-93. Review.


Epitope mapping of a chimeric CD137 mAb: a necessary step for assessing the biologic relevance of non-human primate models.

Chan SL, Voskens CJ, Lin W, Schindler DG, Azimzadeh A, Wang LX, Taylor RJ, Strome SE, Schulze DH.

J Mol Recognit. 2009 May-Jun;22(3):242-9. doi: 10.1002/jmr.937.


FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.

Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, Chapoval A, Schulze DH, Tian G, Strome SE.

Cancer Immunol Immunother. 2009 Jul;58(7):997-1006. doi: 10.1007/s00262-008-0613-3. Epub 2008 Nov 1. Erratum in: Cancer Immunol Immunother. 2009 Sep;58(9):1527-8.


Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies.

Lin W, Voskens CJ, Zhang X, Schindler DG, Wood A, Burch E, Wei Y, Chen L, Tian G, Tamada K, Wang LX, Schulze DH, Mann D, Strome SE.

Blood. 2008 Aug 1;112(3):699-707. doi: 10.1182/blood-2007-11-122465. Epub 2008 Jun 2.

Supplemental Content

Loading ...
Support Center